FDA Update on Rare Breast Implant-Associated Type of Lymphoma

Research and Studies funded and/or conducted by those who benefit monetarily from implants need to be considered when seeking information about implants on the Internet. Web sites de-emphasizing risks associated with implantation are mostly funded by those who have vested interests in these medical devices. The implant industry has profits exceeding billions of dollars per year. This forum contains what they don't want you to know!


RosieS
Loyal Member
Joined: 27 Oct 2013, 09:58

Unread post 01 Apr 2017, 04:33 #1

http://www.medscape.com/viewarticle/877 ... 2880&faf=1

News Alerts >
Medscape Medical
News
FDA Update on Rare Breast Implant-Associated Type of
Lymphoma


Megan Brooks
 | DisclosuresMarch 21, 2017
 

The US Food and Drug Administration (FDA) has provided an update on
breast implant–associatedd anaplastic large cell lymphoma.

In January 2011, the agency identified a

possible association between breast implants and the development of
anaplastic large cell lymphoma (ALCL).

Since then, "we have strengthened our understanding of this
condition and concur with the World Health Organization designation of
breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a
rare T-cell lymphoma that can develop following breast implants,"
the

FDA said in a statement March 21.

OVER 350 CASES, 9 DEATHS


The FDA notes that most data suggest that BIA-ALCL occurs more often
after implantation of breast implants with textured surfaces rather than
those with smooth surfaces.

As of February 1, 2017, the FDA has received a total of 359 medical
device reports (MDRs) of BIA-ALCL, including 9 deaths. Of the 231 reports
that included information on the implant surface, 203 concerned textured
implants and 28, smooth implants.

Of the 312 reports that included information on implant fill types, 186
described implants filled with silicone gel and 126, implants filled with
saline.

"It is important to note that details on breast implant surface and
fill type are limited. While the MDR system is a valuable source of
information, it may contain incomplete, inaccurate, untimely, unverified,
or biased data," the FDA says.

During the last 6 years, a "significant body" of literature has
been published on BIA-ALCL, including additional case histories and
comprehensive reviews of the natural history and long-term outcomes of
the disease, the agency notes.  "All of the information to date
suggests that women with breast implants have a very low but increased
risk of developing ALCL compared to women who do not have breast
implants."

Most cases of BIA-ALCL are treated by removal of the implant and the
capsule surrounding the implant, and some cases have been treated by
chemotherapy and radiation. However, because BIA-ALCL has "generally
only been identified in patients with late onset of symptoms such as
pain, lumps, swelling, or asymmetry, prophylactic breast implant removal
in patients without symptoms or other abnormality is not
recommended," the FDA said.

The exact number of cases of BIA-ALCL worldwide is unknown.

The FDA is continuing to collect and evaluate information about BIA-ALCL.
For now, the agency recommends that clinicians who have patients with
breast implants take the following action:
  • Be aware that most confirmed cases of BIA-ALCL have occurred in women
    with textured breast implants. Provide the manufacturer's labeling as
    well as any other educational materials to your patients before surgery
    and discuss with them the benefits and risks of the different types of
    implants.
  • Consider the possibility of BIA-ALCL in a patient with late-onset,
    persistent peri-implant seroma. In some cases, patients presented with
    capsular contracture or masses adjacent to the breast implant. A patient
    with suspected BIA-ALCL should be referred to an appropriate specialist
    for evaluation. When testing for BIA-ALCL, collect fresh seroma fluid and
    representative portions of the capsule and send for pathology tests to
    rule out BIA-ALCL. Diagnostic evaluation should include cytologic
    evaluation of seroma fluid with Wright-Giemsa–stained smears and cell
    block immunohistochemistry testing for cluster of differentiation and
    anaplastic lymphoma kinase markers.
  • Develop an individualized treatment plan in coordination with the
    patient's multidisciplinary care team. Consider current clinical practice
    guidelines, such as those from the

    Plastic Surgery Foundation or the National Comprehensive Cancer
    Network (NCCN) when choosing your treatment approach.
  • Report all confirmed cases of ALCL in women with breast implants to
    the FDA's MedWatch
    system.
  • Submit case reports of BIA-ALCL to the

    PROFILE Registry  to contribute to a better understanding of the
    causes and treatments of BIA-ALCL.
Reply